Wpływ suplementacji witaminą D na funkcje seksualne oraz objawy depresyjne u młodych kobiet z niskim poziomem witaminy D by Krysiak, Robert et al.
168
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.a2018.0013
Tom/Volume 69; Numer/Number 2/2018
ISSN 0423–104X
The effect of vitamin D supplementation on sexual 
functioning and depressive symptoms in young women with 
low vitamin D status
Wpływ suplementacji witaminą D na funkcje seksualne oraz objawy depresyjne 
u młodych kobiet z niskim poziomem witaminy D
Robert Krysiak1, Anna Szwajkosz2, Bogdan Marek3, 4, Bogusław Okopień1
1Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland 
2Oncology Ward, Beskid Oncology Centre — John Paul II Municipal Hospital in Bielsko-Biała, Poland 
3Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Poland 
4Endocrinological Ward, Third Provincial Hospital, Rybnik, Poland
Abstract
Introduction: Hypovitaminosis D is associated with abnormal female sexual functioning. The aim of our study was to assess whether 
vitamin D supplementation affects sexual functioning and depressive symptoms in young women with low vitamin D status. 
Material and methods: The study included 47 women with vitamin D deficiency or insufficiency. All women with vitamin D deficiency 
were treated with oral vitamin D, while women with vitamin D insufficiency were either treated with vitamin D or left untreated. At the 
beginning of the study and six months later, all patients completed questionnaires evaluating female sexual function (FSFI) and depres-
sive symptoms (BDI-II). 
Results: The total FSFI score and scores in three domains (sexual desire, orgasm, and satisfaction) were lower while the overall BDI-II 
score was higher in women with vitamin D deficiency than in women with vitamin D insufficiency. Vitamin D improved sexual desire 
in women with both vitamin D deficiency and vitamin D insufficiency, increased the total FSFI score and scores for orgasm and sexual 
satisfaction, and decreased the total BDI-II score, in women with vitamin D deficiency.
Conclusions: The obtained results indicate that vitamin D supplementation improves female sexual functioning and mood in women 
with low vitamin D status.  (Endokrynol Pol 2018; 69 (2): 168–174)
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Streszczenie
Wstęp: Niedobór witaminy D łączony jest z nieprawidłowym funkcjonowaniem seksualnym u kobiet. Celem badania było dokonanie 
oceny, czy suplementacja witaminy D ma wpływ na funkcjonowanie seksualne oraz na objawy depresyjne u młodych kobiet z niskim 
poziomem tej witaminy.
Materiał i metody: Badaniem objęto 47 kobiet z brakiem lub niedoborem witaminy D. Wszystkim kobietom z brakiem powyższej witaminy 
podawano egzogenną witaminę D doustnie, zaś kobiety z niedoborem witaminy albo otrzymywały witaminę D albo nie były nią leczone. 
Na początku badań oraz po 6 miesiącach od ich rozpoczęcia wszystkie pacjentki wypełniały kwestionariusze oceniające funkcjonowanie 
seksualne u kobiet (FSFI) oraz objawy depresyjne (BDI-II).
Wyniki: U kobiet z brakiem witaminy D całkowita punktacja FSFI oraz punktacja w zakresie trzech domen ocenianych w tym teście 
(pożądanie seksualne, orgazm, satysfakcja) były niższe, natomiast wartość wskaźnika BDI-II była wyższa w porównaniu z kobietami 
z niedoborem witaminy D. Egzogenna witamina D poprawiła pożądanie seksualne zarówno u kobiet z brakiem i niedoborem witaminy 
D. Ponadto zwiększyła wartość wskaźnika FSFI oraz punktację w zakresie orgazmu i satysfakcji seksualnej, a także zmniejszyła wartość 
wskaźnika BDI-II u kobiet z brakiem witaminy D.
Wnioski: Uzyskane wyniki wskazują, że suplementacja witaminy D w stanach jej niedoboru poprawia funkcjonowanie seksualne oraz 
nastrój u kobiet. (Endokrynol Pol 2018; 69 (2): 168–174)
Słowa kluczowe: objawy depresyjne, 25-hydroksywitamina D, kwestionariusze, funkcjonowanie seksualne, poziom witaminy D
Introduction
Apart from its role in the regulation of calcium and 
phosphorus homeostasis, vitamin D is implicated 
in different physiological processes, including the 
regulation of cellular growth and differentiation, 
glucose metabolism, immune function, and placental 
function [1–3]. These effects are mediated through 
specific receptors, which are located in almost any cell 
and tissue, particularly in the brain, the chest, bones, 
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muscles, and the gastrointestinal tract [4]. Observational 
studies indicate that serum 25-hydoxyvitamin D levels, 
being the most reliable marker of vitamin D status [5], 
predict increased morbidity and mortality [6]. Abnor-
mal production and/or metabolism of vitamin D may 
make individuals particularly susceptible to various car-
diometabolic disorders, such as myocardial infarction, 
stroke, hypertension, and both types of diabetes [7–9] 
as well as to several autoimmune diseases, particularly 
to rheumatoid arthritis, systemic sclerosis, and systemic 
lupus erythematosus [1, 3, 10]. Low vitamin D status 
also seems to be associated with an increased risk of the 
development of various gynaecological and obstetric 
disorders including infertility, endometriosis, polycystic 
ovary syndrome, breast and ovarian cancer, as well as 
gestational diabetes mellitus and preeclampsia [11].
Very little is known about the association between 
vitamin D and sexual functioning. In men with type 2 
diabetes, 25-hydroxyvitamin D levels inversely corre-
lated with the severity of erectile dysfunction assessed 
by the International Index of Erectile Function-5 ques-
tionnaire [12]. A significant proportion of men with 
erectile dysfunction, particularly of arteriogenic aetiol-
ogy, had vitamin D deficiency [13], which suggests that 
low levels of vitamin D may impair erectile function 
by promoting endothelial dysfunction. Vitamin D 
preparations improved erectile function in middle-
aged men, which was accompanied by an increase 
in serum testosterone levels and a beneficial effect 
on the components of the metabolic syndrome [14]. 
Recently, Krysiak et al. [15] have found that vitamin 
D deficiency and insufficiency are also associated with 
impaired female sexual functioning and depressive 
symptoms. The degree of these disturbances inversely 
correlates with vitamin D status. [15]. The aim of the 
present study was to evaluate sexual functioning and 
depressive symptoms in women who, because of low 
vitamin D status, have been treated with vitamin D 
preparations. 
Material and methods
Women (20–40 years old) were eligible for the study if 
they met the criteria of vitamin D deficiency or vitamin 
D insufficiency. Vitamin D deficiency was defined as 
plasma 25-hydroxyvitamin D levels less than 20 ng/mL, 
while vitamin D insufficiency as circulating 25-hy-
droxyvitamin D levels between 20 and 30 ng/mL. To 
minimise the impact of seasonal fluctuations in vitamin 
D status approximately a half of the patients (n = 47) 
were recruited in January and February (n = 22) and 
the other half (n = 25) between July and August. Some 
patients included in the present study participated also 
in our previous one [ ]. The exclusion criteria were as 
follows: any acute or chronic disorder, sexual inactivity, 
pregnancy or lactation, a history of urogynaecological 
operations that might affect sexual function, any phar-
macotherapy, and poor patient compliance. The study 
protocol was approved by the Bioethical Committee 
of the Medical University of Silesia, and all subjects 
included in the study signed informed consent after 
careful explanation of the study procedures.
All patients with vitamin D deficiency (n = 16) were 
then treated with oral vitamin D preparations (4000 IU 
daily) for six months. In turn, the participants with 
vitamin D insufficiency (n = 31) on the basis of patient 
preference were allocated to one of two groups treated 
with oral vitamin D preparations (2000 IU daily; n = 
17) for six months or not receiving vitamin D therapy 
(n = 14). The investigation of possible drug-induced 
side effects was performed fortnightly.
Venous blood samples for laboratory assays were 
collected from the antecubital vein after an overnight 
12-h fasting at 8 a.m. Serum levels of 25-hydroxyvita-
min D were measured by enzyme immunoassay using 
reagents obtained from ALPCO Diagnostics (Windham, 
NH, USA). 
Immediately after blood collection, all participants 
were asked to fill in a questionnaire assessing their 
demographic characteristics, marital status, education, 
general health, medical and sexual history, and physical 
activity, as well as to complete questionnaires investigat-
ing their sexual function (Female Sexual Function Index 
— FSFI) and depressive symptoms (Beck Depression 
Inventory-Second Edition — BDI-II). At this stage of 
the study, neither the women nor the investigators were 
aware of the vitamin D status of the patient. 
FSFI is a standardised questionnaire used world-
wide to assess sexual function within the last four weeks 
and to evaluate the treatment outcome in clinical trials. 
This survey consists of 19 questions, divided into six 
domains: desire (items 1 and 2), arousal (items 3–6), 
lubrication (items 7–10), orgasm (items 11–13), satisfac-
tion (items 14–16), and pain (items 17–19) [16, 17]. Each 
answer is rated from 0 to 5 or 1 to 5. The total FSFI score 
is obtained from the sum of the items in each domain 
multiplied by the domain factor (0.6 for desire, 0.3 for 
arousal and lubrication, and 0.4 for orgasm, satisfaction, 
and pain). Higher scores for each domain and higher 
total scores indicate better sexual function. The total 
FSFI cutoff score for the diagnosis of dysfunction is less 
than 26.55 [16, 17]. 
BDI-II is a valid and reliable indicator of the presence 
and severity of depressive symptoms, corresponding 
well to a clinical diagnosis of depressive disorders de-
scribed in the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition [18, 19]. BDI-II contains 
21 items, each with a four-point scale ranging from 0 to 
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3; total scores range from 0 to 63 (higher scores repre-
senting greater severity of depression). In accordance 
with manual guidelines, the BDI-II was interpreted 
as follows: minimal range = 0–13, mild depression 
= 14–19, moderate depression = 20–28, and severe 
depression = 29–63 [18, 19].
Although all participants underwent laboratory 
tests and filled in the questionnaires, only the data of 
individuals with normal vitamin D status (defined as 
circulating 25-hydroxyvitamin D levels between 30 and 
75  ng/mL) at the end of the treatment and data of all 
vitamin D-naïve women with vitamin D insufficiency 
were included in the final analyses. The normality of 
distribution was determined using the Kolmogorov-
Smirnov test. Natural log transformation was then 
applied to variables not meeting normality. Compari-
sons between the groups were made using analysis of 
covariance followed by Bonferroni post-hoc tests after 
consideration of age, smoking, body mass index, blood 
pressure, marital status, education, occupational activ-
ity, type of work, profession, physical activity, and stress 
exposure as potential confounders. Student’s paired 
t-test was applied to compare pre- and post-therapy 
data within the same treatment group. Qualitative 
variables were compared using the χ2 test. Associations 
were calculated using Pearson’s correlation coefficient 
(r). Differences were considered statistically significant 
at p < 0.05.
Results
General characteristics of the study groups
At baseline, women with vitamin D deficiency and 
both groups of women with vitamin D insufficiency 
were similar in regard to age, body mass index, weight, 
waist circumference, physical activity, education, oc-
cupational activity, type of work, stress exposure, the 
number and duration of marriages, the number of 
deliveries, the number of sexual partners, and blood 
pressure (Table I). 
Vitamin D treatment was well tolerated, and all pa-
tients receiving vitamin D preparations completed the 
study period. Two women with vitamin D deficiency, as 
well as two women with vitamin D insufficiency failed 
to achieve normal vitamin D status and therefore only 
data of 14 vitamin D-treated women with vitamin D 
deficiency, 15 vitamin D-treated women with vitamin 
D insufficiency, and all 14 vitamin D-naïve women 
with vitamin D insufficiency were included in statisti-
cal analyses.
Table I. Baseline characteristics of the study population
Tabela I. Przekrój charakterystyki badanych pacjentów
Vitamin D-treated women 
with vitamin D deficiency
Vitamin D-treated women 
with vitamin D insufficiency
Vitamin D-naïve women  
with vitamin D insufficiency
Number of patients 14 15 14
Age [years; mean (SD)] 30 (6) 31 (5) 30 (5)
Body mass index [kg/m2; mean (SD)] 28.0 (3.5) 27.5 (3.1) 27.3 (4.0)
Smokers (%)/Number of cigarettes a day  
[n; mean (SD)]/Duration of smoking [months,  
mean (SD)]
29/11 (4)/88 (29) 27/11 (5)/90 (32) 29/12 (5)/80 (24)
Physical activity: total/once a week/several times 
a week/ once a month (%)
71/29/21/21 73/27/27/20 79/29/29/21
Primary or vocational/secondary/university 
education (%)
36/36/28 40/40/20 36/36/28
Occupational activity/Blue-collar/white-collar/
pink-collar workers (%)
93/36/36/12 87/27/40/21 86/29/29/29
Number of sexual partners [n; mean (SD)] 2.0 (0.6) 1.9 (0.8) 1.8 (0.7)
Number of marriages [n; mean (SD)]/ duration of 
marriages [months; mean (SD)]
1.1 (0.7)/48 (22) 1.2 (0.6)/53 (29) 1.1 (0.6)
Number of deliveries [n; mean (SD)]/ Number of 
abortions [n; mean (SD)]
1.3 (0.6)/ 0.6 (0.7) 1.5 (0.6)/0.5 (0.6) 1.4 (0.6)/0.7 (0.7)
Stress exposure (%) 79 79 71
Systolic blood pressure [mmHg; mean (SD)] 123 (12) 124 (11) 123 (14)
Diastolic blood pressure [mmHg; mean (SD)] 76 (8) 77 (6) 75 (9)
25-hydroxyvitamin D levels [ng/dL; mean (SD)] 11 (4)a, b 24 (3) 24 (4)
SD — standard deviation; ap < 0.001 vs. vitamin D-treated women with vitamin D insufficiency; bp < 0.001 vs. vitamin D-naive women with vitamin D insufficiency
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Sexual function (Table II)
At baseline, the mean total FSFI score was insignifi-
cantly lower in women with vitamin D deficiency than 
in women with vitamin D insufficiency (p = 0.058). 
Sexual dysfunction was observed in six subjects (43%) 
with vitamin D deficiency and six subjects (21%) with 
vitamin D insufficiency. Women with vitamin D defi-
ciency obtained lower scores in three domains (sexual 
desire, orgasm, and sexual satisfaction) than women 
with vitamin D insufficiency.
Vitamin D administered to women with vitamin 
D deficiency improved sexual desire, orgasm, and 
sexual satisfaction and increased the FSFI score, while 
if administered to women with vitamin D insufficiency, 
it improved only desire. The mean FSFI score and all 
domain scores did not change throughout the study in 
vitamin D-naïve women with vitamin D insufficiency. 
The percentage of patients with sexual dysfunction 
decreased to 14% in vitamin D-treated patients with 
vitamin D deficiency and did not change in the remain-
ing two groups. The effect of vitamin D on the mean 
FSFI score, desire, orgasm, and satisfaction was stronger 
in women with vitamin D deficiency than vitamin D 
insufficiency.
At the end of the study, the mean FSFI score as well 
as all domain scores were similar in both vitamin D-
treated groups. The domain score for desire was lower 
in women with untreated vitamin D deficiency than in 
the remaining groups of women.
Depressive symptoms (Table III)
Compared to women with vitamin D insufficiency, 
women with vitamin D deficiency had insignificantly 
higher values of the BDI-II score (p = 0.062), and were 
characterised by a more frequent occurrence of total 
and mild depressive symptoms.
In women with vitamin D deficiency, vitamin D 
reduced the overall BDI-II score, and decreased the 
Table II. The effect of vitamin D on sexual functioning in young women with low vitamin D status
Tabela II. Wpływ witaminy D na funkcjonowanie seksualne u młodych kobiet z niskim poziomem witaminy D
Variable Vitamin D-treated women with 
vitamin D deficiency
Vitamin D-treated women with 
vitamin D insufficiency
Vitamin D-naïve women with 
vitamin D insufficiency
FSFI score [mean (SD)]
At the beginning of the study
At the end of the study
29.60 (2.47)
32.08 (2.25)e, h
31.61 (2.29)
32.54 (2.54)
31.64 (2.37)
31.53 (2.05)
FSFI score ≤ 26.55 (%)
At the beginning of the study
At the end of the study
43a,c
14f
20
13
21
21
Sexual desire [mean (SD)]
At the beginning of the study
At the end of the study
4.54 (0.56)a, d
5.49 (0.40)c, g, h
5.10 (0.42)
5.56 (0.41)c, e
5.16 (0.41)
5.12 (0.42)
Sexual arousal [mean (SD)]
At the beginning of the study
At the end of the study
5.11 (0.45)
5.31 (0.36)
5.25 (0.42)
5.38 (0.37)
5.34 (0.37)
5.29 (0.42)
Lubrication [mean (SD)]
At the beginning of the study
At the end of the study
5.17 (0.51)
5.34 (0.37)
5.28 (0.43)
5.36 (0.42)
5.25 (0.44)
5.26 (0.44)
Orgasm [mean (SD)]
At the beginning of the study
At the end of the study
4.86 (0.50)b, c
5.36 (0.42)e, h
5.40 (0.49)
5.36 (0.43)
5.42 (0.63)
5.38 (0.43)
Sexual satisfaction [mean (SD)]
At the beginning of the study
At the end of the study
4.80 (0.41)b, d
5.31 (0.40)f, h
5.36 (0.44)
5.48 (0.40)
5.31 (0.46)
5.27 (0.39)
Dyspareunia [mean (SD)]
At the beginning of the study
At the end of the study
5.12 (0.53)
5.27 (0.37)
5.22 (0.64)
5.40 (0.34)
5.16 (0.68)
5.21 (0.36)
SD — standard deviation; ap < 0.05, bp < 0.01 vs. vitamin D-treated women with vitamin D insufficiency; cp < 0.05, dp < 0.01 vs. vitamin D-naïve women with vitamin 
D insufficiency; ep < 0.05, fp < 0.01, gp < 0.001 vs. baseline value; hp < 0.05 — the effect stronger than in vitamin D-treated women with vitamin D insufficiency
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percentage of women with total and mild depressive 
symptoms. In women with vitamin D insufficiency the 
drug tended to reduce BDI-II score (p = 0.075), and the 
percentage of patients with total (p = 0.065) and mild 
(p = 0.065) depressive symptoms, but it did not affect 
the percentage of women with moderate or severe 
depressive symptoms. No changes in the overall BDI-II 
score, as well as the percentage of patients with total, 
mild, moderate, and severe depressive symptoms was 
observed in vitamin D-naïve women with vitamin D 
insufficiency. The effect of vitamin D on the overall 
BDI-II score was stronger in women with vitamin D 
deficiency than vitamin D insufficiency. At the end 
of the study, the overall BDI-II score, as well as the 
percentage of patients with total, mild, moderate, and 
severe depressive symptoms did not differ between 
the study groups. 
Correlations
In all study groups, the mean total FSFI score inversely 
correlated with the total BDI-II score, as well as with 
the percentage of women with total and mild depres-
sive symptoms (vitamin D deficiency: r values between 
–0.30 [p < 0.05] and –0.46 [p < 0.001]; vitamin D insuf-
ficiency: r values between –0.25 [p < 0.05] and –0.43 [p 
< 0.001]), while the BDI-II score positively correlated 
with body mass index (vitamin D deficiency: r = 0.40 [p 
< 0.001]; vitamin D insufficiency: r = 0.47 [p < 0.001]). In 
women with vitamin D deficiency, 25-hydroxyvitamin 
D levels positively correlated with sexual desire (r = 0.47 
[p < 0.001]), orgasm (r = 0.35 [p < 0.01]), and sexual 
satisfaction (r = 0.24 [p < 0.05]), while in women with 
vitamin D insufficiency, 25-hydroxyvitamin D positively 
correlated with desire (r = 0.34 [p < 0.05]). 
The effect of the treatment on the total FSFI score 
inversely correlated with baseline vitamin D levels 
(vitamin D deficiency: r = 0.36 [p < 0.01]; vitamin D 
insufficiency: r = 0.31 [p < 0.05]), and negatively cor-
related with the baseline total BDI-II score (vitamin D 
deficiency: r = 0.29 [p < 0.05]; vitamin D insufficiency: 
r = 0.26 [p < 0.51]), vitamin D-induced changes in 
25-hydroxyvitamin D levels (vitamin D deficiency: 
r = 0.43 [p < 0.001]; vitamin D insufficiency: r = 0.38 
[p < 0.001]), and vitamin D-induced changes in the 
total BDI-II score (vitamin D deficiency: r = 0.35 
[p < 0.01]; vitamin D insufficiency: r = 0.32 [p < 0.05]). 
The changes in the total BDI-II score positively corre-
lated with the changes in 25-hydroxyvitamin D levels 
(vitamin D deficiency: r = 0.34 [p < 0.01]; vitamin 
D insufficiency: r = 0.28 [p < 0.05]). In women with 
vitamin D deficiency, there were positive correlations 
between baseline 25-hydroxyvitamin levels and vitamin 
D-induced changes in sexual desire (r = 0.42 [p < 0.001]), 
orgasm (r = 0.31 [p < 0.05]), and sexual satisfaction 
(r = 0.32 [p < 0.05]), as well as between treatment-
induced changes in 25-hydroxyvitamin D levels and the 
changes in in sexual desire (r = 0.46 [p < 0.001]), orgasm 
(r = 0.28 [p < 0.05]), and sexual satisfaction (r = 0.24 
Table III. The effect of vitamin D on depressive symptoms in young women with low vitamin D status
Tabela III. Wpływ witaminy D na objawy depresyjne u młodych kobiet z niskim poziomem witaminy D
Variable Vitamin D-treated women with 
vitamin D deficiency
Vitamin D-treated women with 
vitamin D insufficiency
Vitamin D-naïve women with 
vitamin D insufficiency
BDI-II score [mean (SD)]
At the beginning of the study
At the end of the study
13.4 (3.8)
9.1 (3.6)d, e
10.2 (2.8)
8.1 (3.0)
10.1 (3.0)
9.8 (3.2)
depressive symptoms [n (%)]
At the beginning of the study
At the end of the study
6 (43)a, b
3 (21)c
3 (20)
1 (7)
3 (21)
3 (21)
mild symptoms [n (%)]
At the beginning of the study
At the end of the study
6 (43)a, b
3 (21)c
3 (20)
1 (7)
3 (21)
3 (21)
moderate symptoms [n (%)]
At the beginning of the study
At the end of the study
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
severe symptoms [n (%)]
At the beginning of the study
At the end of the study
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
SD — standard deviation; ap < 0.05 vs. vitamin D-treated women with vitamin D insufficiency; bp < 0.05 vs. vitamin D-naïve women with vitamin D insufficiency;  
cp < 0.05, dp < 0.01 vs. baseline value; ep < 0.05 — the effect stronger than in vitamin D-treated women with vitamin D insufficiency
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[p < 0.05]). In women with vitamin D insufficiency, 
vitamin D-induced changes in desire inversely corre-
lated with baseline 25-hydroxyvitamin levels (r = –0.29 
[p < 0.05]) and positively with treatment-induced 
changes in 25-hydroxyvitamin levels (r = 0.30 [p < 0.05]).
Discussion
In agreement with the recent study by Krysiak et al. [15], 
women with vitamin D deficiency had impaired sexual 
functioning in comparison to women with vitamin D 
insufficiency. This observation as well as the presence 
of correlations between the total FSFI score and 25-hy-
droxyvitamin D levels support our previous observa-
tions suggesting that a degree of sexual dysfunction 
depends on the severity of vitamin D deficiency. The 
study protocol does not allow us to answer the ques-
tion whether impaired sexual functioning contributes 
to different intensity of depressive symptoms in both 
populations of women and/or is rather its consequence.
However, the most important finding of our study 
was that vitamin D supplementation improved sexual 
dysfunction, which was accompanied by an improve-
ment in mood. Interestingly, vitamin D affected func-
tioning in exactly the same domains of FSFI in which 
patients presented worse scores in comparison with 
healthy women, namely in sexual desire, orgasm, and 
sexual satisfaction in subjects with 25-hydroxyvitamin D 
levels below 20 ng/mL, as well as in sexual desire in 
women with 25-hydroxyvitamin D levels between 20 
and 30 ng/mL. Although the number of domain scores 
affected by the treatment was higher and the strength 
of vitamin D action was greater in subjects with vita-
min D deficiency than insufficiency, this discrepancy 
probably reflects differences in baseline sexual func-
tioning of both groups. In line with this hypothesis, 
the impact on FSFI score and domain scores correlated 
with baseline- and treatment-induced changes in 25-hy-
droxyvitamin D levels. It seems reasonable to assume 
that post-treatment sexual functioning does not differ 
between individuals effectively treated with vitamin D 
and healthy women included in the previous study [15] 
(women with normal vitamin D status were not partici-
pants of the present study). In this study, we took into 
consideration only results of women in whom vitamin 
D normalised 25-hydroxyvitamin D levels, eliminating 
these subjects in whom the supplementary treatment 
did not fully restore normal vitamin D status. This al-
lows us to conclude that sexual dysfunction in women 
with vitamin D deficiency is fully reversible provided 
they are effectively treated with exogenous vitamin D.
Vitamin D was found to increase endothelial ni-
tric oxide production [20], which was observed to be 
impaired in the case of hypovitaminosis D [21, 22]. 
Moreover, low vitamin D levels are associated with 
an increased risk of atherosclerosis, coronary artery 
disease, stroke, hypertension, heart failure, dyslipidae-
mia and atrial fibrillation [8, 9, 23, 24], low serum levels 
of testosterone, and low free androgen index [25], as 
well as with an increased risk of both autonomic and 
peripheral neuropathy [26, 27]. These findings taken 
together indicate that the effects on the cardiovascular 
system, androgen production, and the nervous system 
may mediate the impact of this vitamin on female sexual 
functioning. It is possible that genital blood flow, as well 
as hormonal and neural regulations of sexual function 
are disturbed in women with hypovitaminosis D and 
correlate with its severity, while a normalisation of 
vitamin D status by normalising these disturbances 
may restore normal sexual functioning. Although post-
treatment sexual functioning did not differ from that 
observed in healthy subjects, we cannot exclude that 
at least some disturbances mentioned above, if lasting 
for a long time, may be, at least in part, irreversible.
Some clinical studies conducted so far have shown 
that low circulating levels of 25-hydroxyvitamin D 
are associated with poor mood and that vitamin D 
supplementation improves depressive symptoms 
[28, 29]. In line with these results, mild depressive 
symptoms occurred more frequently in women with 
vitamin D deficiency than vitamin D insufficiency, 
and supplementary treatment reduced BDI-II and the 
percentage of patients with total and mild depressive 
symptoms in both groups of women with low vitamin 
D status, as well as that this effect was significant only 
in the first group of patients. This action may result 
from stimulation of specific receptors expressed in 
the hypothalamus, thalamus, prefrontal cortex, and 
hippocampus [30], which are brain regions involved 
in mood regulation. Through affecting these recep-
tors, vitamin D may modulate central dopaminergic 
and/or serotoninergic neurotransmission and/or affect 
hypothalamic-pituitary-adrenal axis response to stress. 
The presence of correlations both at entry and during 
treatment clearly suggests that sexual dysfunction and 
depressive symptoms are reciprocally interrelated. 
Because these correlations are weak, we may assume 
that sexual dysfunction is important but is not the only 
factor playing a role in the development of depressive 
symptoms. Another factor that seems to contribute 
to depressive symptoms is excessive weight in many 
participants, because the body mass index correlated 
with BDI-II score both at baseline and after treatment.
Our study has some limitations that must be con-
sidered. Its main limitation is the small number of par-
ticipants, which means that larger studies are required 
to confirm our results. FSFI and BDI-II scoring systems, 
like other self-report inventories, are subjective in 
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nature. It cannot be totally excluded that seasonal 
variation in 25-hydroxyvitamin D concentrations, 
observed at high latitudes [31], may have an impact 
on the obtained results. Finally, the effect of vitamin 
D supplementation may be different (probably less 
pronounced) in women suffering from concomitant 
disorders and/or taking other drugs.
Summing up, the total FSFI score and scores in 
three domains (sexual desire, orgasm, and satisfaction) 
were lower while the overall BDI-II score was higher in 
women with vitamin D deficiency than in subjects with 
vitamin D insufficiency. Exogenous vitamin D improved 
desire and depressive symptoms in both treated groups, 
and increased scores for orgasm and sexual satisfaction 
in individuals with vitamin D deficiency. The results of 
the study suggest that vitamin D produces a beneficial 
effect on female sexual functioning and mood in women 
with low vitamin D status.
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